the impact of co-enzyme q10 (coq10) and alpha lipoic acid on pcos women in terms of serum lipid profile, weight loss and resistin level

Background & objective: the present study was conducted with aim to evaluate the effect of combined administration of metformin, ala and coq10 on pcos women in terms of weight reduction, serum lipid profile and insulin resistance.materials & methods: this single-blind randomized controlled clinical trial was conducted in diwaniyah, iraq, from october 2024 to june 2025. participants were randomly assigned to three different groups. patients in group met. received glucophage (500 mg; merck, west drayton, uk) three times per day; group met. +ala were given metformin as in the first group along with ala (600 mg, batch no. 6n5483; holzkrichen, bavaria, germany) three times daily; group met.+ala+coq10 received metformin and ala as in the second group, along with 200 mg of coq10 each day. all treatments were provided over a duration of 12 weeks.results: post-treatment, all three forms of management showed significant decline in average body mass index, cholesterol, triglyceride and ldl and increase in hdl (p<0.001); the effect of met. plus, ala plus coq10 was significantly more profound when contrasted to other 2 modes of therapy (p<0.05). however, none of these treatment approaches were able to significantly affect serum levels of resistin (p>0.05).conclusion: the supplements of alpha lipoic acid and coq10 are efficient and safe in improving outcome of metformin for treatment of pcos afflicted women with respect to weight reduction, and improvement of serum lipid profile.